Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Alimera Sciences (ALIM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.85 per share a year ago. These figures ...

Alimera Sciences (NASDAQ:ALIM) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (NASDAQ:EYPT). That agreement has Alimera Sciences acquiring additional ...

$3.90 310.26% HC Wainwright & Co.

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose ...

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on ...

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to ...

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...